Association of calcium and vitamin D supplementation with cancer incidence and cause-specific mortality in Black women: Extended follow-up of the Women's Health Initiative calcium-vitamin D trial.

What Was Tested

Researchers studied Vitamin D, K2, Magnesium and Zinc in this randomized controlled trial publication.

The researchers analyzed the Women's Health Initiative (WHI) calcium plus vitamin D (CaD) randomized clinical trial extended follow-up data to evaluate associations between calcium plus vitamin D supplementation and incident cancer, cardiovascular disease (CVD), and cause-specific mortality endpoints among Black women.

Why It Was Studied

Low circulating vitamin D levels are more prevalent in Black than White individuals.

Who Took Part

According to the abstract, 3325 women were involved.

PubMed tags the participants as women only.

How the Study Was Run

The researchers set it up as a randomized and placebo-controlled study.

Because people in this Vitamin D, K2, Magnesium and Zinc study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

A placebo (an inactive look-alike) gave the Vitamin D, K2, Magnesium and Zinc group a baseline to be compared against.

What Was Measured

Low circulating vitamin D levels are more prevalent in Black than White individuals.

Topics PubMed links to this paper include Calcium, Cause of Death, Incidence, Dietary Supplements, Vitamin D, Calcium, Dietary and Women's Health.

Author keywords: Black, postmenopausal women and randomized clinical trial.

What This Means in Plain Language

The paper is a randomized and placebo-controlled study of Vitamin D, K2, Magnesium and Zinc in 3325 women.

With several hundred people or more, it is a fairly large study for this kind of research.

The publication is from 2023 (International journal of cancer), a journal based in United States.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.